The Ubiquitin+Proteasome protein degradation pathway as a therapeutic strategy in the treatment of solid tumor malignancies

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 2, 2011, Pages 242-246

  Driscoll, James J ^a   Minter, Alex ^a,b   Driscoll, Daniel A ^c   Burris, Jason K ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c HARVARD UNIVERSITY   (United States)

Author keywords

Bortezomib; Proteasome; Solid Tumors; Ubiquitin

Indexed keywords

BORTEZOMIB; IMATINIB; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG RESEARCH; HUMAN; MULTIPLE MYELOMA; NONHUMAN; PROTEIN DEGRADATION; SOLID TUMOR;

EID: 79953773349     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152011795255948     Document Type: Article

References (62)

1. Hershko, A.; Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem., 1998, 67, 425-479.
2. Glickman, M.H.; Ciechanover, A. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol. Rev., 2002, 82, 373-428.
3. Voorhees, P.M.; Dees, E.C.; O'Neil, B.; Orlowski, R.Z. The proteasome as a target for cancer therapy. Clin. Cancer Res., 2009, 9, 6316-6325.
4. Ganoth, D.; Leshinsky, E.; Eytan, E.; Hershko, A. A multicomponent system that degrades proteins conjugated to ubiquitin. Resolution of factors and evidence for ATP-dependent complex formation. J. Biol. Chem., 1988, 263, 12412-12419.
5. Driscoll, J.; Goldberg, A.L. The proteasome (multicatalytic protease) is a component of the 1500-kDa proteolytic complex which degrades ubiquitin-conjugated proteins. J. Biol. Chem., 1990, 265, 4789-4792.
6. Weissman, A.M. Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell Biol., 2001, 2, 169-178.
7. Hoeller, D.; Dikic, I. Targeting the ubiquitin in cancer therapy. Nature, 2008, 458 438-444.
8. Mani, A.; Gelmann, E.P. The ubiquitin-proteasome pathway and its role in cancer. J. Clin. Oncol., 2005, 23, 4776-89.
9. Orlowski, R. Z.; Eswara, J. R.; Lafond-Walker, A.; Grever, M. R.; Orlowski, M.; Dang, C. V. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res., 1998, 58, 4342-4348.
10. Masdehors, P.; Omura, S.; Merle-Beral, H.; Mentz, F.; Cosset, J. M.; Dumont, J.; Magdelenat, H.; Delic, J. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br. J. Haematol., 1999, 105, 752-757.
11. Soligo, D.; Servida, F.; Delia, D.; Fontanella, E.; Lamorte, G.; Caneva, L.; Fumiatti, R.; Lambertenghi Deliliers G. The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br. J. Haematol., 2001, 113, 126-135.
12. Hideshima, T.; Richardson, P.; Chauhan, D.; Palombella, V. J.; Elliott, P. J.; Adams, J.; Anderson, K. C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res., 2001, 61, 3071-3076.
13. Voorhees, P.M.; Dees, E.C.; O'Neil, B; Orlowski, R.Z. The proteasome as a target for cancer therapy. Clin. Cancer Res., 2003, 9(17), 6316-6325.
14. Drexler, H. C. Activation of the cell death program by inhibition of proteasome function. Proc. Natl. Acad. Sci. USA, 1997, 94, 855-860.
15. Lopes, U. G.; Erhardt, P.; Yao, R.; Cooper, G. M. p53-dependent induction of apoptosis by proteasome inhibitors. J. Biol. Chem., 1997, 272, 12893-12896.
16. Delic, J.; Masdehors, P.; Omura, S.; Cosset, J. M.; Dumont, J.; Binet, J. L.; Magdelenat, H. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo-and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-α-initiated apoptosis. Br. J. Cancer, 1998, 77, 1103-1107.
17. An, B.; Goldfarb, R. H.; Siman, R.; Dou, Q. P. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ, 1998, 5, 1062-1075.
18. Masdehors, P.; Merle-Beral, H.; Maloum, K.; Omura, S.; Magdelenat, H.; Delic, J. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood, 2000, 96, 269-274.
19. Loda, M.; Cukor, B.; Tam, S.W.; Lavin, P.; Fiorentino, M.; Draetta, G. F.; Jessup, J. M.; Pagano, M. Increased proteasomedependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med., 1997, 3, 231-234.
20. Chiarle, R.; Budel, L. M.; Skolnik, J.; Frizzera, G.; Chilosi, M.; Corato, A.; Pizzolo, G.; Magidson, J.; Montagnoli, A.; Pagano, M.; Maes, B.; De Wolf-Peeters, C.; Inghirami, G. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood, 2000, 95, 619-626.
21. Li, B.; Dou, Q. P. Bax degradation by the ubiquitin/proteasomedependent pathway: involvement in tumor survival and progression. Proc. Natl. Acad. Sci. USA, 2000, 97, 3850-3855.
22. McConkey, D.J.; Zhu, K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resistance Updates, 2008, 11 164-179.
23. Orlowski, R.Z. The proteasome inhibitor bortezomib. Nat. Clin. Pract. Oncol., 2006, 3, 16-17.
24. Orlowski, R.Z.; Kuhn, D.J. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin. Cancer Res. 2008, 14, 1649-57.
25. Nencioni, A.; Grünebach, F.; Patrone, F.; Ballestrero, A.; Brossart, P. Proteasome inhibitors: antitumor effects and beyond. Leukemia, 2002, 21, 30-6.
26. Kumar, S.; Rajkumar, S.V. Many facets of bortezomib resistance/ susceptibility. Blood, 2008, 112, 2177-2178.
27. Oerlemans, R.; Franke, N.E.; Assaraf, Y.G.; Cloos, J, van Zantwijk, I.; Berkers, C.R. Jensenn, G. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood, 2008, 112, 2489-2499.
28. Ri, S Iida; T Nakashima; H Miyazaki; F Mori; A Ito; A Inagaki; S Kusumoto; T Ishida; H. Komatsu; Y Shiotsu; R Ueda. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia, 2010, 24, 1506-1512.
29. Pérez-Galán, P.; Mora-Jensen, H.; Weniger, M.A, et al. Bortezomib resistance in mantle cell lymphoma is associated with expression of a plasmacytoid differentiation program. Blood, 2011, 117, 26-38.
30. Shringarpure, R; Catley, L; Bhole, D, Burger, R; Podar, K.; Tai, Y.T.; Kessler, B.; Galardy, P.; Ploegh, H.; Tassone, P.; Hideshima, T.; Mitsiades, C.; Munshi, N.C.; Chauhan, D.; Anderson, K.C. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br. J. Hem., 2006, 34(2), 145-156.
31. Cusack JC; Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat. Rev., 2003, 29, Suppl 1: 21-31.
32. Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Richardson PG; Hideshima T; Munshi N; Treon SP; Anderson KC. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 2002, 99, 4079-86.
33. Hideshima, T.; D. Chauhan; P. Richardson; C. Mitsiades; N. Mitsiades; T. Hayashi; N. Munshi; L. Dang; A. Castro; V. Palombella,; J. Adams; K. C. Anderson. NF-kappa B as a therapeutic target in multiple myeloma. J. Biol. Chem. 2002, 277: 16639-16647.
34. Ogiso Y; Tomida A; Lei S; Omura S; Tsuruo T. Proteasome inhibition circumvents solid tumor resistance to topoisomerase IIdirected drugs. Cancer Res. 2002, 60:2429-2434.
35. Lee, A.S.; Mammalian stress response: induction of the glucoseregulated protein family. Curr. Opin. Cell. Biol., 1992, 4: 267-273.
36. Adams J; The proteasome: a suitable antineoplastic target. Nat Rev Cancer, 2004, 349-60.
37. Milano, A; Perri, F; Caponigro, F. The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib. OncoTargets and Therapy, 2009, 2 171-178.
38. Wright, J.J.; Combination therapy of Bortezomib with novel targeted agents: An emerging treatment strategy. Clin. Cancer Res., 2010, 16, 4094-4104.
39. Boccadoro, M.; Morgan, G.; Cavenagh, J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int., 2005, 18.
40. Williamson, M.J.; Silva, M.D.; Terkelsen, J.; Robertson, R.; Yu, L.; Xia, C.; Hatsis, P.; Bannerman, B.; Babcock, T.; Cao, Y.; Kupperman, E.; The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models. Mol. Cancer Ther., 2008, 8, 3234-3243.
41. Wood, L.D.; Leary, R.J.; Shen, D.; Boca, S.M.; Barber, T.; Ptak, J.; Silliman, N.; Szabo, S.; Dezso, Z.; Ustyanksky, V.; Nikolskaya, T.; Nikolsky, Y.; Karchin, R.; Wilson, P.A.; Kaminker, J.A.; Zhang, Z.; Croshaw, R.; Willis, J.; Dawson, D.; Shipitsin, M.; Willson, J.K.V.; Sukumar, S.; Polyak, K.; Park, B.H.; Pethiyagoda, C.L.; Pant, P.V.K.; Ballinger, D.G.; Sparks, A.B.; Hartigan, J.; Smith, D. R.; Suh, E.; Papadopoulos, N.; Buckhaults, P.; Markowitz, S.D.; Parmigiani, G.; Kinzler, K.W.; Velculescu, V.E.; Vogelstein, B. The genomic landscapes of human breast and colorectal cancers. Science, 2007, 318, 1108-1113.
42. LoPiccolo, J.; Blumenthal, G.M.; Bernstein, W.B.; Dennis, P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resistance Updates, 2008, 11(1-2), 32-50.
43. Di Cosimo, S.; Scaltriti, M.; Val, D.; et al. The PI3-K/AKT/mTOR pathway as a target for breast cancer therapy. Jour. Clin. Onc., 2007, part I, 25(18S), 3511.
44. Morgensztern, D.; McLeod, H.L. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anti-cancer Drugs, 2005, 16(8), 797-803.
45. Chen, K.F.; Yeh, P.Y.; Hsu, C. et al. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem., 2009, 284, 11121-33.
46. Sos, M.L.; Koker, M.; Weir, B.A.; Heynck, S.; Rabinovsky, R.; Zander, T.; Seeger, J.M.; Weiss, J.; Fischer, F.; Frommolt, P.; Michel, K.; Peifer, M.; Mermel, C.; Girard, L.; Peyton, M.; Gazdar, A.F.; Minna, J.D.; Garraway, L.A.; Kashkar, H.; Pao, W.; Meyerson, M.; Thomas, R.K. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res., 2009, 69, 3256-3261.
47. Engelman, J.A.; Janne, P.A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall cell lung cancer. Clin. Cancer Res., 2008, 14. 2895-2899.
48. Vogelstein, B.; Kinzler, K.W. Cancer genes and the pathways they control. Nat. Med., 2004, 10, 789-799.
49. Amit, I.; Citri, A.; Shay, T.; Lu, Y.; Katz, M.; Zhang, F.; Tarcic, G.; Siwak, D.; Lahad, J.; Jacob-Hirsch, J.; Amariglio, N.; Vaisman, N.; Segal, E.; Rechavi, G.; Alon, U.; Mills, GB.; Domany, E.; Yarden, Y. A module of negative feedback regulators defines growth factor signaling. Nat. Genet., 2000, 39, 503-512.
50. Driscoll, J.; Brown, M.; Finley, D.; Monaco, J.J. MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature, 1993, 365, 262-264.
51. Driscoll, J.; Finley, D. A Controlled Breakdown: Antigen Processing and the Turnover of Viral Proteins. Cell, 1992, 68, 823-825.
52. Busse, A.; Kraus, M.; Na, I.K.; Rietz, A.; Scheibenbogen, C.; Driessen, C.; Blau, I.W.; Thiel, E.; Keilholz, U. Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. Cancer, 2008, 12, 657-70.
53. Altun, M.; P.J.; Galardy, R.; Shringarpure, T.; Hideshima, R.; LeBlanc, K.C.; Anderson, H. L.; Ploegh, B. M. Kessler. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res., 2005, 65, 7896-7901.
54. Kuhn, D.J.; Hunsucker, S.A.; Chen, Q.; Voorhees, P.M.; Orlowski, M.; Orlowski, R.Z. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood, 2009, 113, 4667-4676.
55. Joazeiro, C.A.; Anderson, K.C.; Hunter, T. Proteasome inhibitor drugs on the rise. Cancer Res., 2006, 66, 7840-7842.
56. Preckel, T.; Fung-Leung, W. P.; Cai, Z.; Vitiello, A.; Salter-Cid, L.; Winqvist, O.; Wolfe, T.G.; Von Herrath, M.; Angulo, A.; Ghazal, P.; Lee, J.D.; Fourie, A.M.; Wu, Y.; Pang, J.; Ngo, K.; Peterson, P.A.; Fruh, K.; Yang, Y. Impaired immunoproteasome assembly and immune responses in PA28-/-mice. Science, (Wash. DC), 1999, 286, 2162-2165.
57. Groettrup, M.; Soza, A.; Eggers, M.; Kuehn, L.; Dick, T. P.; Schild, H.; Rammensee, H. G.; Koszinowski, U. H.; Kloetzel, P-M. A role for the proteasome regulator PA28α in antigen presentation. Nature, 1996, 381, 166-168.
58. Kopito, R.R. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol.; 2000, 10, 524-530.
59. Kawaguchi, Y.; Kovacs, J.J.; McLaurin, A.; Vance, J.M.; Ito, A.; Yao, T.P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell, 2003, 115, 727-738.
60. Kraft, C.; Peter, M. and Hofmann, K. Selective autophagy: ubiquitin-mediated recognition and beyond. Nature Cell Biol. 2010, 12, 836-841.
61. Driscoll, J.J.; Pelluru, D.; Lefkimmiatis, K.; Fulciniti, M.; Prabhala, R.H.; Greipp, P.R.; Barlogie, B.; Tai, Y.T.; Anderson, K.C.; Shaughnessy, J.D. Jr, Annunziata, C.M.; Munshi, N.C. The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood, 2010, 115(14), 2827-34.
62. Soucy, T.A.; Smith, P.G.; Milhollen, MA.; Berger, A.J.; Gavin, J.M.; Adhikari, S.; Brownell, J.E.; Burke, K.E.; Cardin, D.P.; Critchley, S.; Cullis, C.A.; Doucette, A.; Garnsey, J.J.; Gaulin, J.L.; Gershman, R.E.; Lublinsky, A.R.; McDonald, A.; Mizutani, H.; Narayanan, U.; Olhava, E.J.; Peluso. S.; Rezaei, M.; Sintchak, M.D.; Talreja. T.; Thomas, M.P.; Traore, T.; Vyskocil, S.; Weatherhead, G.S.; Yu, J.; Zhang, J.; Dick, L.R.; Claiborne, C.F.; Rolfe, M.; Bolen, J.B.; Langston, S.P. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature, 2009, 458(7239), 732-736.